Ketohexokinase Inhibition in MASLD: Metabolic Benefits
Ketohexokinase (KHK) inhibition provides significant metabolic benefits in MASLD patients, including reduction in liver fat, improvement in insulin resistance, decreased hepatic inflammation, and reversal of hypertriglyceridemia, though current evidence shows these benefits are investigational and not yet approved for clinical use.
Evidence from Clinical Trials
The most robust human data comes from a Phase 2 randomized controlled trial of the KHK inhibitor PF-06835919 in adults with NAFLD/MASLD 1. In this 6-week study, the 300 mg dose reduced whole liver fat by 18.73% compared to placebo (p=0.04) and improved inflammatory markers, with good safety and tolerability profiles. This represents the highest-quality clinical evidence available for KHK inhibition in humans with MASLD.
Mechanistic Metabolic Benefits
Hepatic Improvements
KHK inhibition targets fructose metabolism at its first committed step, producing multiple downstream metabolic benefits:
- Reduced hepatic steatosis: Both through decreased de novo lipogenesis (DNL) and increased fatty acid oxidation, depending on the mechanism of KHK targeting 2, 3
- Decreased liver inflammation: Demonstrated in human trials with reduction in inflammatory markers 1
- Improved liver injury markers: Reduced serum transaminases in preclinical models 3
- Reduced fibrogenesis: Human liver tissue studies show decreased fibrogenic gene expression with KHK inhibition 3
Systemic Metabolic Benefits
Beyond hepatic effects, KHK inhibition improves multiple metabolic parameters 4:
- Reversal of hyperinsulinemia: Improved insulin sensitivity in animal models fed both high-fructose and standard American diets
- Correction of hypertriglyceridemia: Significant reductions in serum triglycerides
- Improved glucose tolerance: Though this effect may vary depending on whether KHK is inhibited versus knocked down 2
- Reduced uric acid production: Via the intestinal-liver-kidney axis 5
Critical Mechanistic Distinctions
An important caveat emerges from recent research: The method of KHK targeting matters significantly 2. Small molecule KHK inhibitors (like PF-06835919) produce partial inhibition of fructolysis and may also inhibit triokinase, leading to fructose-1-phosphate accumulation. This can cause:
- Glycogen accumulation and hepatomegaly
- Impaired glucose tolerance
- Potential hepatocyte injury
In contrast, complete KHK knockdown (via siRNA) prevents hepatic fructolysis entirely and shows superior glucose tolerance improvements 2. This suggests that next-generation KHK inhibitors may need to achieve more complete target inhibition or employ alternative strategies like hepatocyte-specific siRNA to maximize metabolic benefits while avoiding off-target effects.
Tissue-Specific Considerations
Intestinal KHK plays a crucial role in fructose absorption and metabolism 5. Intestinal-specific KHK deletion in mice ameliorated:
- Hepatic steatosis and liver injury
- Glucose and insulin resistance
- Colonic epithelial barrier integrity
- Adipose tissue remodeling
This suggests that targeting intestinal KHK specifically may offer advantages by reducing fructose exposure before it reaches the liver, potentially avoiding some hepatic complications seen with systemic KHK inhibition.
Current Clinical Development Status
While the 2024 EASL-EASD-EASO guidelines 6 do not specifically recommend KHK inhibitors (as they remain investigational), they emphasize the need to:
- Determine weight loss-independent mechanisms of MASLD improvement
- Evaluate the impact of controlling metabolic comorbidities on hepatic disease
- Assess whether improvement in steatotic liver injury benefits metabolic dysfunction
KHK inhibition addresses all three priorities by targeting fructose metabolism independent of weight loss, improving both hepatic and systemic metabolic parameters.
Practical Implications
The metabolic benefits of KHK inhibition are mechanistically sound and clinically demonstrated, but this remains an investigational approach. PF-06835919 has completed Phase 2 trials, and the second-generation inhibitor LY3522348 has finished Phase 1 evaluation 7.
Key unresolved issues include:
- Isoform selectivity (KHK-C vs KHK-A targeting)
- Tissue-specific delivery optimization
- Long-term safety, particularly regarding glycogen accumulation
- Optimal dosing to achieve complete fructolysis inhibition without off-target effects
Until regulatory approval, the metabolic benefits of KHK inhibition remain a promising but not yet clinically available therapeutic strategy for MASLD patients.